We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acadia Healthcare (ACHC) Down 15.1% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Acadia Healthcare (ACHC - Free Report) . Shares have lost about 15.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Acadia Healthcare due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Acadia Healthcare Misses on Q3 Earnings, Trims View
Acadia Healthcare Company, Inc. (ACHC - Free Report) reported third-quarter 2018 adjusted earnings of 55 cents per share, which missed the Zacks Consensus Estimate by 15%. The bottom line also declined 5.2% year over year.
Earnings missed due to rise in expenses that negatively impacted EBITDA margin.
Quarterly Details
In the reported quarter, revenues rose 6.2% year over year to $760.9 million. However, the top line fell short of the Zacks Consensus Estimate by 0.3%.
Total same facility revenues grew 6.2% with a 2.4% increase in patient days and a 3.8% rise in revenues per patient day. U.S. same facility revenues were up 7.2% year over year to $478.9 million.
The company also recorded a 3.3% increase in patient days year over year and 3.8% growth in revenue per patient day.
U.K. same facility revenues rose 4.4% year over year to $245.4 million. The number of patient days inched up 1.3% from the year-earlier period while revenues per patient per day improved 3.1%.
Total same facility EBITDA margin contracted 100 basis points year over year to 23.9%.
Total expenses increased 7.7% year over year to $705.9 million, courtesy of higher salaries, professional fees, supplies, wages and benefits, interest expenses, depreciation and amortization as well as rents and leases.
During the third quarter, Acadia Healthcare added 132 beds to existing facilities, bringing the total up to 806 beds added to new and existing facilities since the end of third-quarter 2017.
Financial Update
Cash and cash equivalents as of Sep 30, 2018 were $48.9 million, down 27.3% from the 2017-end level.
Long-term debt amounted to $3.18 billion as of Sep 30, 2018, up 0.7% from the 2017-end level.
Net cash provided by operating activities at the end of nine months was $286.2 million, up nearly 5.5% year over year.
2018 Guidance Lowered
For 2018, the company expects adjusted earnings per share between $2.25 and $2.27 (down from the previous projection of $2.52-$2.56) on revenues of approximately $3 billion (down from the earlier estimate of $3.02-$3.06 billion). Adjusted EBITDA is anticipated between $605 million and $610 million (compared with the former forecast of $632-$639 million). Furthermore, the company expects to add more than 800 beds to existing and new facilities in 2018.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -27.53% due to these changes.
VGM Scores
At this time, Acadia Healthcare has a subpar Growth Score of D, a grade with the same score on the momentum front. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Acadia Healthcare has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Acadia Healthcare (ACHC) Down 15.1% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Acadia Healthcare (ACHC - Free Report) . Shares have lost about 15.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Acadia Healthcare due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Acadia Healthcare Misses on Q3 Earnings, Trims View
Acadia Healthcare Company, Inc. (ACHC - Free Report) reported third-quarter 2018 adjusted earnings of 55 cents per share, which missed the Zacks Consensus Estimate by 15%. The bottom line also declined 5.2% year over year.
Earnings missed due to rise in expenses that negatively impacted EBITDA margin.
Quarterly Details
In the reported quarter, revenues rose 6.2% year over year to $760.9 million. However, the top line fell short of the Zacks Consensus Estimate by 0.3%.
Total same facility revenues grew 6.2% with a 2.4% increase in patient days and a 3.8% rise in revenues per patient day.
U.S. same facility revenues were up 7.2% year over year to $478.9 million.
The company also recorded a 3.3% increase in patient days year over year and 3.8% growth in revenue per patient day.
U.K. same facility revenues rose 4.4% year over year to $245.4 million. The number of patient days inched up 1.3% from the year-earlier period while revenues per patient per day improved 3.1%.
Total same facility EBITDA margin contracted 100 basis points year over year to 23.9%.
Total expenses increased 7.7% year over year to $705.9 million, courtesy of higher salaries, professional fees, supplies, wages and benefits, interest expenses, depreciation and amortization as well as rents and leases.
During the third quarter, Acadia Healthcare added 132 beds to existing facilities, bringing the total up to 806 beds added to new and existing facilities since the end of third-quarter 2017.
Financial Update
Cash and cash equivalents as of Sep 30, 2018 were $48.9 million, down 27.3% from the 2017-end level.
Long-term debt amounted to $3.18 billion as of Sep 30, 2018, up 0.7% from the 2017-end level.
Net cash provided by operating activities at the end of nine months was $286.2 million, up nearly 5.5% year over year.
2018 Guidance Lowered
For 2018, the company expects adjusted earnings per share between $2.25 and $2.27 (down from the previous projection of $2.52-$2.56) on revenues of approximately $3 billion (down from the earlier estimate of $3.02-$3.06 billion). Adjusted EBITDA is anticipated between $605 million and $610 million (compared with the former forecast of $632-$639 million).
Furthermore, the company expects to add more than 800 beds to existing and new facilities in 2018.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -27.53% due to these changes.
VGM Scores
At this time, Acadia Healthcare has a subpar Growth Score of D, a grade with the same score on the momentum front. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Acadia Healthcare has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.